Nicotinamide adenine dinucleotide (NAD+) sits at the centre of cellular energy metabolism, and its tissue levels fall measurably with age. This article reviews, for research audiences only, what the primary literature actually reports about that decline, its mechanisms, and the NAD+ precursor trials that have followed.

Why researchers study NAD+ in ageing

Nicotinamide adenine dinucleotide is a coenzyme present in every living cell, where it cycles between oxidised (NAD+) and reduced (NADH) forms to carry electrons through central energy pathways. Beyond that redox role, NAD+ is an obligatory co-substrate for a group of enzymes, including sirtuins, poly(ADP-ribose) polymerases (PARPs) and the NADase CD38, that consume it during signalling reactions.¹ Because these enzymes touch DNA repair, chromatin remodelling, cellular senescence and immune function, the size of the intracellular NAD+ pool has become a recurring variable in geroscience research.

A consistent observation across the literature is that NAD+ availability decreases with age. A comprehensive review in Nature Reviews Molecular Cell Biology summarised evidence that tissue and cellular NAD+ levels decline gradually in multiple model organisms, and that this decline has been linked causally, in animal models, to several ageing-associated conditions.¹ A separate 2023 Endocrine Reviews appraisal framed age-related loss of NAD+ bioavailability as a postulated contributor to many age-related diseases, while emphasising that the clinical pharmacology and therapeutic mechanisms remain incompletely understood.¹⁰ That tension, a robust preclinical signal alongside genuinely open human questions, defines the current research landscape.

What NAD+ does inside the cell

The redox function of NAD+ is the most established. As NAD+/NADH, the coenzyme shuttles reducing equivalents into oxidative phosphorylation, making it indispensable to mitochondrial adenosine triphosphate (ATP) generation. This is why experimental depletion of NAD+ so reliably compromises bioenergetic capacity in cultured cells and rodent tissues.¹

The second function is as a consumed substrate. Sirtuins are NAD+-dependent deacylases that regulate transcription, metabolic adaptation and mitochondrial biogenesis; their activity is gated by how much NAD+ is available. PARPs consume NAD+ during the DNA damage response. CD38, an ectoenzyme highly expressed on immune cells, hydrolyses NAD+ and its precursors and is a major route of NAD+ turnover in tissue.³ Because these enzymes draw on the same pool, their combined demand can outpace synthesis, and researchers study NAD+ as a shared currency whose depletion propagates across several pathways at once.

In the nervous system, a 2019 Cell Metabolism review catalogued NAD+-dependent enzymes involved in synaptic plasticity and neuronal stress resistance, positioning NAD+ metabolism as a candidate node in brain ageing and neurodegeneration research.⁴ These are mechanistic and model-organism findings; they describe biology observed in cells and animals, not demonstrated clinical outcomes in people.

Mechanisms of age-related NAD+ decline

A central question in the field has been why NAD+ falls with age, whether synthesis slows, consumption rises, or both. Work from the Chini laboratory identified CD38 as a decisive factor: in mice, CD38 expression and NADase activity increase with age, and CD38 is required for the age-related decline in NAD+ and the accompanying mitochondrial dysfunction, acting through a pathway that involves regulation of SIRT3.³ The same study identified CD38 as the principal enzyme degrading the precursor nicotinamide mononucleotide in vivo, a detail that directly shapes how precursor-repletion strategies are interpreted.

A complementary mechanism connects this to cellular senescence. Research published in Nature Metabolism showed that pro-inflammatory, CD38-expressing macrophages accumulate in metabolic tissues such as visceral adipose and liver during ageing, and that factors secreted by senescent cells (the senescence-associated secretory phenotype) drive these macrophages to proliferate and raise their CD38 activity, thereby lowering tissue NAD+.² In this model, NAD+ decline is not a passive fading of supply but an active consequence of an inflammatory, senescent tissue environment.

These mechanistic threads matter for how any repletion approach is framed. If a large fraction of tissue NAD+ is being consumed by CD38 on inflammatory cells, then simply adding substrate addresses only one side of a supply-and-demand equation, a nuance the primary literature is careful to preserve.²

NAD+ versus its precursors: a dosing distinction

An important clarification often lost in general writing: the large majority of controlled human data concern NAD+ precursors, principally nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), rather than NAD+ molecule itself administered orally. NAD+ is a comparatively large, charged dinucleotide, and the pharmacology of raising intracellular NAD+ is generally studied by supplying the smaller biosynthetic building blocks that cells convert to NAD+ internally.¹⁰

Where precursor dose-response has been measured directly, the data are quantitative. In an 8-week randomised, double-blind, placebo-controlled trial in overweight but otherwise healthy adults, oral NR at 100, 300 and 1000 mg per day raised whole-blood NAD+ by roughly 22%, 51% and 142% respectively within two weeks, with the increases maintained across the study and no significant difference in adverse events versus placebo.⁶ That study illustrates why "how much precursor" is a meaningful research variable, and why milligram figures such as those attached to research NAD+ preparations are best read as pharmacokinetic reference points rather than efficacy claims. For laboratories comparing repletion strategies, direct NAD+ preparations such as Qovigen NAD+ 500 mg and precursor or mitochondrial-signalling compounds like MOTS-C represent distinct experimental levers on the same broad energy-metabolism question.

Research domains under investigation

Preclinical and early clinical work has probed NAD+ biology across several organ systems. The table below summarises the direction of the evidence and the model system in which it was chiefly generated, so that the evidence tier is visible alongside each domain.

The pattern is instructive. The strongest, most reproducible effects are mechanistic and in animals; the human read-outs that exist are either pharmacokinetic (NAD+ rose) or exploratory functional signals that call for larger confirmatory trials.

Metabolic and vascular signals

The clearest human functional result to date comes from skeletal muscle. In a 10-week randomised, placebo-controlled, double-blind trial, NMN supplementation increased insulin-stimulated glucose disposal and skeletal-muscle insulin signalling in postmenopausal women with prediabetes who were overweight or obese, while placebo did not.⁹ On the vascular side, chronic NR in healthy middle-aged and older adults was well tolerated and robustly raised NAD+ metabolism; the authors reported an initial suggestion of reduced blood pressure and arterial stiffness and explicitly framed it as a hypothesis for future, adequately powered trials rather than an established outcome.⁷

Neuronal models

In the nervous system the evidence is almost entirely preclinical. A widely cited Nature Neuroscience study demonstrated that stimulating mitophagy, including via NAD+ supplementation, reduced amyloid-β and tau pathology and reversed memory deficits in nematode and mouse models of Alzheimer's disease.⁵ These are model-organism results; the corresponding human cognition trial found that NR raised blood NAD+ but left cognitive scores unchanged over its duration.⁸ The gap between animal mechanism and human endpoint is exactly what the field is now working to close.

What human trials actually report

Reading the human literature honestly means separating two claims: that precursors raise NAD+, which is well supported, and that this produces downstream clinical benefit, which remains largely unproven in the strict sense. The Endocrine Reviews appraisal put it plainly: early human studies show NAD+ can be raised in blood and some tissues by oral precursors, but the clinical pharmacology and therapeutic mechanisms are incompletely understood, and adequately powered randomised trials are still needed to evaluate efficacy for metabolic and age-related conditions.¹⁰

The mild cognitive impairment trial is a useful case study in this discipline. It achieved its pharmacological target, a 2.6-fold rise in blood NAD+, and NR was well tolerated with no between-group difference in adverse events. Yet the primary cognitive outcome remained stable, and secondary imaging findings would not have survived correction for multiple comparisons. The authors concluded that a larger, longer trial is required.⁸ Positive pharmacokinetics with neutral functional endpoints is a recurring shape in this literature, and any research interpretation should hold both facts together.

Open questions and handling notes

Several questions remain genuinely unresolved. It is not established how efficiently a rise in blood NAD+ translates to specific tissues, nor whether adding substrate meaningfully overcomes elevated CD38-mediated consumption in an aged, inflammatory environment.² The optimal chemical form, direct NAD+ versus NR versus NMN, has not been settled by head-to-head human comparison, and long-term outcome data are sparse.¹⁰

For laboratory work, research materials of this class are typically supplied as a lyophilised powder for reconstitution and are handled under standard cold-chain and sterile-technique practice; investigators should consult the accompanying certificate of analysis for identity and purity data. None of the compounds discussed here is an approved therapeutic, and the observations above describe experimental systems, not recommended human use.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.